Abstract

Oncolytic viruses have the capacity to induce anti-tumour immune responses by the direct lysis of cancer cells and liberation of tumour antigens. We have developed strategies to enhance this capacity by creating oncolytic vaccines that encode tumour antigens while retaining their oncolytic activity. I will discuss the development of our Maraba virus based technology and its use in combination therapy approaches.